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Autism spectrum disorders (ASDs) and related neurological disorders are associated with mutations in many
genes affecting the ratio between neuronal excitation and inhibition. However, understanding the impact of
these mutations on network activity is complicated by the plasticity of these networks, making it difficult in
many cases to separate initial deficits from homeostatic compensation. Here we explore the contrasting ev-
idence for primary defects in inhibition or excitation in ASDs and attempt to integrate the findings in terms of
the brain’s ability to maintain functional homeostasis.A Theory of Excitatory/Inhibitory Imbalance in Autism
Over 10 years ago, John Rubenstein and Michael Merzenich
published an influential review (Rubenstein and Merzenich,
2003) suggesting that autism and related disorders might reflect
an increase in the ratio between excitation and inhibition leading
to hyper-excitability of cortical circuits. The theory was attractive
because it provided a potential explanation for the frequent
observation of reduced GABAergic signaling in the brains of au-
tistics (Cellot and Cherubini, 2014), as well as their propensity to
develop epilepsy. In addition, since inhibition was known or
believed to contribute to sharpening the selectivity of excitatory
responses inmany brain areas, the loss of inhibition could lead to
enhanced ‘‘noise’’ and imprecision in learning and cognition.
Since this initial formulation, however, other studies have sug-
gested a nearly opposite hypothesis; namely, that at least
some Autism Spectrum Disorders (ASDs) are characterized by
a reduction in the ratio between excitation and inhibition. In
this Review, we first summarize some of the major lines of evi-
dence supporting primary increases and decreases in the ratio
of excitatory to inhibitory synaptic transmission in Autism and
related disorders. We then argue that a homeostatic view of
how activity propagates through cortical circuits predicts such
contradictory findings and offers a framework for integrating
them.
It is important to acknowledge at the outset that the concept of
a single ‘‘E/I balance’’ determining whether brain circuits are
normal or ‘‘autistic’’ is obviously overly simplistic. This is true
both because different microcircuits in different brain regions
may be characterized by different mixtures of excitation and in-
hibition and because even within a single microcircuit different
sources of excitation and inhibition affect different aspects of
neuronal function and target distinct cellular compartments.
For example, in sensory regions of neocortex, pyramidal neurons
receive excitatory synaptic input from different sources on
different portions of their dendritic trees (Petreanu et al., 2009).
Here, as in the rest of the forebrain, specific populations of inter-
neurons are specialized to regulate distinct subcellular compart-
ments (Kepecs and Fishell, 2014). Therefore, the ratio between
excitation and inhibition may vary from one cellular component
to another. There is a paucity of studies that have addressed684 Neuron 87, August 19, 2015 ª2015 Elsevier Inc.the effects of autism-related mutations on these different com-
ponents of excitatory and inhibitory transmission. Nor is it
straightforward to define a single physiological measurement
that accurately captures the balance between excitation and in-
hibition. One recent study measured both the excitatory and
inhibitory evoked synaptic input to visual cortical pyramidal neu-
rons and found that although total input varied between cells the
ratio of excitatory and inhibitory input was constant (Xue et al.,
2014). Furthermore, perturbing the activity of pyramidal neurons
perturbed this balance specifically by changing the strength of
perisomatic inhibition mediated by parvalbumin-postive inteur-
neurons. Despite the complexities of defining and measuring
the excitatory/inhibitory ratio, we think there are good reasons
that the concept continues to be an influential one in thinking
about the misregulation of brain circuits in developmental disor-
ders. Since many of the signaling molecules and activity-depen-
dent processes that affect excitatory synapses (and some clas-
ses of inhibitory synapses) are conserved across multiple brain
regions, it is not unreasonable to suppose the existence of ge-
netic conditions that could initially affect a distributed set of glu-
tamatergic or GABAergic synapses. In addition, although we are
trying to identify pathophysiological threads linking diverse ASDs
as well as other developmental disorders, it is clear that these
disorders are highly heterogeneous and may have unique mech-
anisms and consequences. We focus primarily on monogenic
syndromes, even though these represent only about 10% of
ASDs, because the ability to model these syndromes in animals
allows testing of specific hypotheses about circuit dysfunction.
Evidence for Primary Inhibitory Dysfunction in ASD
Autistic patients develop epilepsy at a rate up to 25 times that of
the general population (Bolton et al., 2011). Epilepsy is the med-
ical disorder most commonly associated with Autism, occurring
in up to one-third of affected individuals (Muhle et al., 2004). The
prevalence of epileptiform EEG without overt seizures is even
higher. Although the association may vary as diagnostic criteria
for ASDs are altered, even the exclusion of particular populations
such as patients with Rett Syndrome, who have especially high
rates of epilepsy (e.g., 70%), is unlikely to dramatically reduce
the overall association (Gilby and O’Brien, 2013).
Table 1. Summary of Monogenic Forms of Autism
Syndrome Seizure Onset Molecular Target Clinical Review Molecular Mechanism Review
ARX mutations Neonatal–4 months ARX Lux and Osborne (2006) Olivetti and Noebels (2012);
Shoubridge et al. (2010)
Dravet Syndrome First year of life Scn1a/NAV1.1 Brunklaus et al. (2012) Oakley et al. (2011)
Tuberous Sclerosis First year of life TCS1/2 Curatolo et al. (2008) Crino (2013); Lasarge and
Danzer (2014)
Fragile X Between ages 4 and
10 years
FMRP Heard et al. (2014) Bhakar et al. (2012); Darnell
and Klann (2013); Santoro et al.
(2012)
Angelman Syndrome Mean 1 year 1 month
‘‘85% of patients within the
first three years of life, although
less than 25% develop
seizures during the first year’’
Ube3a Valente et al. (2006);
Laan and Vein (2005);
Thibert et al. (2013)
Mabb et al. (2011)
Rett Syndrome Between ages 2 and 5 years MeCP2 Dolce et al. (2013);
Neul et al. (2010)
Guy et al. (2011); Katz et al.
(2012); Samaco and
Neul (2011)
NRXN1
mutations
Varies with mutation NRXN1 Be´na et al. (2013) Su¨dhof (2008)
GPHN mutations Varies with mutation GPHN Lionel et al. (2013) Tyagarajan and Fritschy (2014)
SHANK mutation, Phelan
McDermid Syndrome
Increase with age for PM
syndrome, not well
characterized for mutations
restricted to Shank3
Shank1,2,3 Guilmatre et al. (2014);
Sarasua et al. (2014)
Jiang and Ehlers (2013)
CNTNAP2 mutations Between ages 2 and 7 years CNTNAP2 Jackman et al. (2009);
Lesca et al. (2012)
Pen˜agarikano and Geschwind
(2012)
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ASDs, it is perhaps not surprising that individual syndromes vary
in the typical age range of onset of epilepsy relative to other as-
pects of the disorder (Table 1). Some genetic causes of ASDs are
virtually invariably associated with early-onset epilepsy, and we
hypothesize that these are more likely to reflect primary deficits
in inhibition because of the lack of an asymptomatic period dur-
ing which homeostatic compensation could develop. Rescue
experiments showing the reversal of symptoms is the gold stan-
dard for establishing a causal impact. However, for develop-
mental disorders that affect differentiation and cell migration,
reversal could be difficult to achieve in an adult animal. In these
cases, the etiology can be analyzed via modeling the disorder in
a selective cellular subpopulation. This way, in a number of
cases, the etiology can be traced rather directly to failures in
the normal neurogenesis, migration, differentiation, and/or func-
tion of cortical interneurons. One of the defining examples of
such a syndrome involves mutation in the transcription factor
Aristaless (ARX) in which major subsets of forebrain interneurons
fail to migrate into the cortex from the medial ganglionic
eminence leading to profound and early-onset seizures and ma-
jor disruptions of cognitive development (for review, see Shou-
bridge et al., 2010). Knocking ARX out selectively in forebrain in-
terneurons recapitulates many symptoms seen in human
mutations (Marsh et al., 2009), leading to the idea of an ‘‘inter-
neuronopathy’’ responsible for the epilepsy. Malformation phe-
notypes (e.g., agenesis of the corpus callosum) are not present
in the interneuron-specific KO, presumably reflecting additionalroles for this gene in other neuronal subtypes such as excitatory
neuron progenitors that cause the malformation phenotype.
Another syndrome in which severe childhood epilepsy is
linked to autistic symptoms is Dravet’s Syndrome, usually
caused by heterozygous loss of function of the sodium channel
subunit Scn1a. Recent work indicates that knocking out one
copy of the channel selectively in forebrain GABAergic neurons
recapitulates all the major symptoms including seizures, hyper-
activity, social dysfunction, anxiety, ataxia, and sleep disorders
(Cheah et al., 2012; Han et al., 2012; Ito et al., 2013; Tai et al.,
2014). This appears to be a case in which a channelopathy pro-
duces an interneuronopathy sinceNaV1.1 (the protein product of
Scn1a) is localized to the axon initial segments of parvalbumin
positive (Pv+) fast-spiking and Somatostatin-positive (SST) inter-
neurons in the neocortex and hippocampus, as well as to pur-
kinje neurons of the cerebellum, which also exhibit fast-spiking
behavior. Loss of function of one allele of Scn1a prevents sus-
tained fast spiking (FS) in Pv+ neurons (Ogiwara et al., 2007)
and decreases seizure threshold even when this manipulation
is largely restricted to these neurons (Dutton et al., 2013).
Scn1a is only one of several sodium channel subunits that are
upregulated in Pv+ FS interneurons during the period of develop-
ment when they begin to exhibit fast-spiking behavior (Okaty
et al., 2009) and several of these including scn1b, scn8a, and
scn9a have also been associated with Dravet Syndrome itself
(Scn1b), or with modifying Dravet Syndrome susceptibility
(scn9a) or with other epilepsy syndromes (Meisler et al., 2010).
It is important to point out that even the conditional mutantsNeuron 87, August 19, 2015 ª2015 Elsevier Inc. 685
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the sufficiency of the loss of function in specific inhibitory neu-
rons to produce particular symptoms. It is not unlikely that for
some symptoms of autistic patients with these mutations, alter-
ations in other cells and circuits also contribute and indeed
genetic background can influence cellular phenotypes of the
haploinsufficiency in mice (Rubinstein et al., 2015) and contribu-
tions of the haploinsufficiency in subsets of excitatory neurons
modify the seizure phenotype without producing effects on their
own (Ogiwara et al., 2013). Demonstrating that the mutation in
specific forebrain inhibitory neurons is not only sufficient but
also necessary would require selectively rescuing the behavioral
phenotype by rescuing the effects of the mutation in those cells.
Although genetic rescue experiments have not yet been
performed, behavioral symptoms in a mouse model of Dravet’s
syndrome are suppressed by pharmacological increase in
GABAergic neurotransmission, pinning a deficit of inhibitory
transmission as the cause of these symptoms (Han et al., 2012).
Another genetic disorder associated with seizures and autistic
behaviors is Tuberous Sclerosis (TS), named for the presence of
cortical malformations called tubers. The disorder is caused by
mutations in Tsc1 (hamartin) and Tsc2 (tuberin), which together
exist in a complex that inhibits mTOR (mammalian target of rapa-
mycin) signaling, thereby regulating translational machinery and
growth inmany tissues. Epilepsy is present in the vast majority of
patients and 20%–60% of TS patients meet diagnostic criteria
for autism (Numis et al., 2011). The pathophysiology of this dis-
order is still far from clear. For example, although tubers have
long been suspected to be the source of epileptic activity and
are still removed surgically in TS patients with intractable epi-
lepsy, a number of mouse models of the disorder present with
spontaneous seizures but lack tubers (Goorden et al., 2007; Loz-
ovaya et al., 2014). In addition, recordings in patients suggest tu-
bers are electrically silent, focusing the search for epileptic foci
on surrounding tissue (Schwartzkroin and Wenzel, 2012). Dele-
tion of Tsc1 in glia and/or neural progenitors produces seizures
(for review, see Wong and Crino, 2012), as does deletion in fore-
brain excitatory neurons, suggestingmultiple potential pathways
for generating seizures from loss of function of the TS complex.
One recent study performed detailed physiological analyses
following sparse cre-mediated deletion of a conditional Tsc1
allele in hippocampal neurons. Bateup and colleagues (Bateup
et al., 2013) concluded that the primary, cell-autonomous deficit
was a reduction in inhibitory input to pyramidal neurons. In addi-
tion to cell-autonomous postsynaptic effects (presumed to be on
GABA receptors), reduced presynaptic release was also seen
with more widespread deletion of Tsc1. Effects on neuronal
excitability and on excitatory synapses were also present but
were in the wrong direction to produce circuit hyperexcitability
and were instead presumed to reflect homeostatic responses
of the circuit to abnormal activity. Although this study demon-
strated critical effects of deleting Tsc1 in pyramidal neurons
and largely ruled out a contribution to the observed results
from loss of mTOR signaling in interneurons, another study
recently demonstrated increased mortality and decreased
seizure threshold in mice in which Tsc1 was selectively deleted
from interneuron progenitors using a Dlx5/6 cre driver strain
(Fu et al., 2012). Studies reporting positive effects of deleting686 Neuron 87, August 19, 2015 ª2015 Elsevier Inc.Tsc1 in inhibitory neurons and glia highlight the difficulty of
teasing apart primary from secondary effects and raise the pos-
sibility that disruption of core biological pathways, like themTOR
pathway, can lead to multiple primary effects in different cell
types. The approach of cell-type-specific deletion can help
clarify this situation. For example, the Bateup et al. study above
reversed earlier conclusions from the same group that the
network hyperexcitability was due to a primary deficit in LTD
and a corresponding enhancement of excitatory synaptic trans-
mission (Bateup et al., 2011). A similar ‘‘embarrassment of
riches’’ in terms of primary and secondary effects is present for
other ASDs that result from disruptions of pathways serving
important roles in many cell types.
Like TS, Fragile X syndrome (FXS) and Angelman Syndrome
(AS) target aspects of protein metabolism critical for synaptic
function, and also like TS, both FXS and AS have been associ-
ated with abnormalities of both excitatory and inhibitory synaptic
transmission. FMRP (Fragile X Mental Retardation Protein) is an
RNA binding protein linked to trafficking and translation of syn-
aptic proteins (Darnell et al., 2011), which when knocked out in
mouse recapitulates many features of the disorder (Brennan
et al., 2006; Musumeci et al., 2000; The Dutch-Belgian Fragile
X Consortium, 1994). One prominent theory of FXS (see also
below) posits that FMRP loss of function leads to exaggerated
long-term depression (LTD) of excitatory synapses (Bear et al.,
2004). Abnormal long-term plasticity at excitatory synapses is
the pathophysiological mechanism pursued in most studies,
but large changes in GABAergic transmission have also been re-
ported. For example, in the amygdala GABAergic transmission is
reduced, as is the expression of GABA synthesis enzymes and
some receptors, although the effects have a complex time
course and vary across brain regions (Lozano et al., 2014). Disin-
hibition may also contribute to the abnormal plasticity seen at
excitatory synapses, and the metabotropic glutamate receptors
contributing to the pathophysiology of the disease may be
located both on glutamatergic and GABAergic neurons (Palusz-
kiewicz et al., 2011).
Angelman Syndrome is a disorder of protein degradation,
rather than synthesis. It is due in large part to loss of function
of the E3 ubiquitin ligase UBE3A. In mice, as in humans,
Ube3a is imprinted in the brain and the disease arises from
loss of expression of the maternal allele. Although there is evi-
dence for reduced excitatory synaptic transmission (see below),
a recent study found diminished inhibition occurring late (post-
natal day 80 [P80]) but not earlier (P25) (Wallace et al., 2012).
The reduced inhibition was due to changes in the probability
with which FS neurons contacted pyramidal neurons and to pre-
synaptic reductions in the strength of these connections and
those made by some other interneuron classes. Excitatory and
inhibitory input to FS cells were unaffected. The numbers of in-
terneurons of various classes and the inhibitory quantal ampli-
tude were also not altered. Although genetic lesions restricted
to Ube3a can produce AS, more commonly the disorder is
caused by a larger maternal deletion affecting other nearby
genes. In particular, haploinsufficency of Gabrb3 (a GABA-A
beta subunit) is believed to contribute to the much more severe
epilepsy seen in these patients than in those with lesions
restricted to Ube3a (Tanaka et al., 2012).
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recently been hypothesized to underlie Rett Syndrome (RTT).
Initially, symptoms of RTT were believed to reflect primarily de-
fects in glutamatergic (see below) as well as aminergic neurons
(Samaco et al., 2009), but more recent work has suggested fea-
tures of the disorder may arise from actions of MeCP2 in a wide
variety of cell types including not only multiple subtypes of neu-
rons, but also astrocytes (Lioy et al., 2011) andmicroglia (Derecki
et al., 2012). Evidence that inhibitory circuits are involved comes
most directly from knockout (KO) of a conditional MeCP2 allele in
all GABAergic neurons driven by a Viaat-Cre BAC transgenic
(Chao et al., 2010). In keeping with physiological studies of res-
piratory function in global KO mice (Viemari et al., 2005), these
mice have abnormalities of brainstem inhibitory circuits and
develop respiratory insufficiency leading to premature death.
Respiratory symptoms do not develop in mice in which fore-
brain-specific deletion of Mecp2 in GABAergic neurons is driven
by a Dlx5/6-Cre strain, although this manipulation is reported to
produce many other symptoms present in the Viaat cre KO
including stereotypies, learning deficits, and social abnormal-
ities. Some of these symptoms probably reflect loss in striatal
neurons, but changes in inhibitory synaptic transmission were
also seen in neocortex, where GABA, its synthesis enzymes,
and inhibitory quantal amplitude were reportedly reduced.
Changes in inhibitory quantal amplitude were not observed in
studies of Mecp2 global KOs (Dani et al., 2005; Nelson et al.,
2006), perhaps reflecting differences in the preparations studied
(L2/3 versus L5 or hippocampal cultures). Intriguingly, forebrain-
selective KO in GABA neurons did not produce seizures or
epileptiform activity, suggesting that seizures in this disorder
arise through a non-cell-autonomous effect on inhibition or
through enhanced excitation in some circuits. In another recent
study, cell-type-specific deletion of MeCP2 from excitatory neu-
rons either through widely or sparsely expressing Cre in
neocortex and hippocampus also resulted in hyperexcitation
but through a decrease of inhibitory spontaneous and evoked
neurotransmission ontoMeCP2-deficient excitatory cells (Zhang
et al., 2014). Both of these studies use cell-type-specific
knockout approaches to conclude that in the absence of
MeCP2, the primary defect is decrease of inhibition, but whether
this defect arises from the loss of MeCP2 function in excitatory,
inhibitory, or glial cells remains debated. One possibility is that,
perhaps as for Tsc1, gene function is needed simultaneously in
multiple cell types to maintain normal transmission.
Many of the ASD models described above involve primary al-
terations in the transcription, translation, trafficking, or degrada-
tion of synaptic proteins. Other monogenic models of ASD
implicate specific synaptic proteins themselves (Ebert and
Greenberg, 2013; De Rubeis et al., 2014). These include ion
channels and receptors (like the sodium channels, and gluta-
mate and GABA receptor subunits described above), cell adhe-
sion molecules, which promote the formation and function of
synapses between specific classes of pre- and postsynaptic
neurons, and synaptic scaffolding molecules that link compo-
nents of synaptic signaling cascades. In some cases, these mol-
ecules are differentially expressed at excitatory and inhibitory
synapses providing insights into the likely initial pathophysiolog-
ical deficit. For example, the synaptic cell adhesion moleculesNeuroligins1–4 and their binding partners, Neurexins, have
been implicated in ASD (Durand et al., 2007; Gauthier et al.,
2009; Jamain et al., 2003; Laumonnier et al., 2004; Vaags
et al., 2012). Neuroligin 1 is primarily localized to excitatory syn-
apses (Song et al., 1999), while Neuroligin 2 is mostly present at
inhibitory synapses (Varoqueaux et al., 2004), Neuroligin 3 is pre-
sent at both (Budreck and Scheiffele, 2007), and Neuroligin 4 is
localized to glycinergic synapses (Hoon et al., 2011). While
both Neuroligin 3 and Neuroligin 4 mutations are associated
with ASD, the mouse Neuroligin 4 gene exhibits a high degree
of sequence divergence from the human orthologs (Bolliger
et al., 2008), thus complicating the interpretation of the data
from the mouse models. Nevertheless, evidence for primary
inhibitory dysfunction comes from mice missing Neuroligins1–3,
which have impaired evoked and spontaneousGABAergic/glyci-
nergic transmission in the brainstem (Varoqueaux et al., 2006).
Their presynaptic binding partners, Neurexins, also have multi-
ple isoforms (Ullrich et al., 1995) and may differentially regulate
synaptic function depending on the neurotransmitter type (Chih
et al., 2006). Mutation in contactin associated protein-like 2
(CNTNAP2), a protein from the Neurexin superfamily, causes
childhood-onset epilepsy along with language regression, intel-
lectual disability, hyperactivity, and autism (Strauss et al., 2006).
In a mouse model, loss of CNTNAP2 leads to hyperactivity and
seizures, defects in neuronal migration, and a reduced number
of GABAergic cells (Pen˜agarikano et al., 2011). A related protein,
CNTNAP4, is enriched in cortical interneurons and midbrain
dopaminergic cells and localizes to synapses and is also associ-
ated with ASD (Fernandez et al., 2004; Roohi et al., 2009).
Knockout of this gene results in autistic-like repetitive behaviors
and mild epileptiform-like activity in mice. While there is a
decrease in the output of the PV-positive interneurons, an in-
crease in dopaminergic neurotransmission is also observed
(Karayannis et al., 2014).
Scaffolding proteins are responsible for clustering and local-
izing postsynaptic receptors and, like adhesion molecules,
have synapse-type specificity. Gephyrin is the scaffolding mole-
cule that localizes to the postsynaptic side of inhibitory synapses
and controls GABA and glycine receptor localization and clus-
tering (Tyagarajan and Fritschy, 2014). Deletions overlapping
with the gephyrin genomic region are associated with ASD and
seizure phenotypes (Dejanovic et al., 2014; Lionel et al., 2013).
Reduction of Gephyrin levels expression with shRNA knock-
down (Jacob et al., 2005) or a mutation (Kneussel et al., 1999)
reduced GABA receptor clustering but not overall surface
expression leading to decreased GABAergic and glycinergic
synaptic currents (Kneussel et al., 1999).
Evidence for Primary Excitatory Dysfunction in ASD
Contrary to Rubenstein and Merzenich’s original hypothesis,
work on multiple animal models of ASDs and other develop-
mental disorders suggest a shift in the balance between excita-
tion and inhibition away from excitation. An early suggestion that
Autism may be a hypoglutamatergic disorder (Carlsson, 1998)
was based (as was a similar hypothesis for schizophrenia) on
the preponderance of glutamatergic neurons in implicated brain
structures including the amygdala, hippocampus, and neocortex
and on the ability of some glutamate antagonists to mimic someNeuron 87, August 19, 2015 ª2015 Elsevier Inc. 687
Figure 1. Summary of Brain Activity Mapping in Mecp2 Mutant Mice
Based on Fos Expression
Low Fos expression in the motor cortex (Mctx) and adjacent regions indicates
decreased activity while there is higher Fos expression in the nucleus of the
solitary tract (nTS) and nearby areas. Differences in Fos expression in the
Mecp2 null brain compared to wild-type are color coded as follows: red, Null <
WT; green, Null > WT. Reproduced with permission from Kron et al. (2012).
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bition, has been proposed to account for learning deficits in
Down syndrome (DS) (Belichenko et al., 2009; Fernandez et al.,
2007; Kleschevnikov et al., 2004), a disorder sharing many
symptomatic components with ASD (Channell et al., 2015). For
instance, DS patients also show restricted and repetitive behav-
iors (Evans et al., 2014), a core symptom in ASD (Leekam et al.,
2011). We hypothesize that the similarity in symptoms of this
developmental disorder with ASD might indicate the presence
of analogous deficits in the brains of autistic patients.
Both enhanced inhibition and reduced excitation have been
observed in mouse models of the developmental disorder Rett
Syndrome (Dani et al., 2005), although the reduced excitation
is a larger effect and has been replicated across a variety of prep-
arations including synaptically connected neocortical pyramidal
neurons from knockout mice (Dani and Nelson, 2009), hippo-
campal neurons cultured from knockout mice (Nelson et al.,
2006), and induced pluripotent stem cells from human Rett pa-
tients (Marchetto et al., 2010). This effect is cell autonomous
as shown by sparse knockdown in cultured rat neocortical neu-
rons (Blackman et al., 2012) or by recordings from autaptic cul-
tures of hippocampal neurons from knockout mice (Chao et al.,
2007). These experiments also link loss of Mecp2 in a specific
cell population to the disease symptoms. In order to make a
full connection, however, rescue experiments are necessary. In
case of Rett syndrome, removing a stop codon or introducing
a wild-type version of the gene late in development has been
shown to alleviate some of the symptoms in the mouse models
(Giacometti et al., 2007; Garg et al., 2013; Guy et al., 2007). How-
ever, these experiments are complicated by the need to match
the precise level of the MeCP2 gene expression since too
much can also lead to deleterious effects (Jiang et al., 2013; Pe-
tazzi et al., 2014). Several forms of excitatory synaptic plasticity
have been reported to be altered following loss of function of
Mecp2. Initial studies observed reductions in LTP at hippocam-
pal and neocortical synapses (Asaka et al., 2006; Moretti et al.,
2006), although subsequent work has suggested that this may
be secondary to the shift in the ratio between excitation and in-
hibition, since LTP at neocortical synapses was normal when
providing sufficient postsynaptic depolarization (Dani and
Nelson, 2009). LTP is also reported to be blocked following over-
expression of Mecp2, a manipulation that increases mEPSC fre-
quency without apparent effects on inhibition (Na et al., 2012).
Homeostatic synaptic plasticity also appears to be disrupted
by loss of Mecp2. Synaptic scaling up in response to reduced
activity (Blackman et al., 2012) and scaling down in response
to elevated activity (Qiu et al., 2012; Zhong et al., 2012) are
both reduced. For scaling up, this has been demonstrated
both by cell-autonomous knockdown in culture and in slices
from knockout mice following sensory manipulations in vivo
(Blackman et al., 2012). In the thalamus, strengthening and expe-
rience-dependent remodeling of retinogeniculate synapses is
altered in Mecp2 KOmice, even though earlier phases of synap-
tic development in this pathway are normal (Noutel et al., 2011).
Given the fact that Mecp2 has important roles not only in
GABAergic neurons and glutamatergic neurons, but also in other
neuronal and nonneuronal cell types, how can the net effect on
the excitability of brain circuits be predicted? Kron, Katz, and688 Neuron 87, August 19, 2015 ª2015 Elsevier Inc.colleagues have recently used immediate-early gene expression
to map overall activity levels throughout the brains of Mecp2 KO
mice (Kron et al., 2012). The results are striking and show
increased activity within the nucleus tractus solitarus, a structure
known to be involved in cardiorespiratory symptoms of the dis-
order but overall reduced activity within much of the forebrain
including the cerebral cortex and subcortical limbic structures
(Figure 1). Hence within the forebrain, reduced excitation ap-
pears to predominate over reduced inhibition. A new platform
for carrying out this type of analysis brain-wide, but with cellular
resolution, may improve our understanding of the net effects on
activity of other mutations with complex biology (Kim et al.,
2015).
Abnormalities of excitatory synaptic function in Angelman
Syndrome (AS) include changes in the threshold for LTP and
LTD induction, more transient LTP, reduced density and size of
dendritic spines, reduced mEPSC frequency, and reductions in
the AMPA/NMDA ratio (for review, see Mabb et al., 2011).
Each of these impairments of excitatory synaptic transmission
may be limited to particular sets of synapses, ages, or conditions
but may contribute to impaired learning and sensory plasticity.
Specific substrates of ubiquitination underlying these abnormal-
ities include Arc, an immediate-early gene important for multiple
forms of Hebbian and homeostatic plasticity at excitatory synap-
ses (Greer et al., 2010), and Ephexin-5 (Margolis et al., 2010),
which regulates excitatory synapse number during development
(Kaphzan et al., 2012).
Rodent models of TS were initially found to exhibit reduced
LTP (Ehninger et al., 2008) but more recent studies have demon-
strated a profound loss of protein synthesis-dependent, mGluR-
mediated LTD (Auerbach et al., 2011; Bateup et al., 2011) leading
to upregulation of excitatory synaptic transmission. However, as
noted above, cell-type-specific knockout suggests that these
changes in excitation may be secondary to reduced inhibition.
MGluR-mediated LTD is also the form of synaptic plasticity
most closely implicated in the pathogenesis of FXS (Waung
and Huber, 2009) and the two mutations were found to produce
opposing effects on synaptic plasticity and learning behavior in
mice (Auerbach et al., 2011). A recent sequencing study identi-
fied mTOR and Tsc2 as targets of FMRP and hypothesized
that increased FMRP regulation is induced by upregulation of
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2012). This would provide a mechanistic explanation for the abil-
ity of removal of fmr1 to normalize the phenotype of TS.
The idea that FXS is due to overactive LTD implies that excit-
atory synaptic transmission is weakened in this syndrome. There
is ample evidence that this is the case, but the defects observed
vary developmentally and with the specific pathway studied. In
the somatosensory cortex, the first major intracortical relay link-
ing L4 neurons to L2/3 is initially weaker andmore diffuse but this
regularizes with development (Bureau et al., 2008). At the same
time, there is a potent and lasting reduction in the excitatory drive
from L4 neurons onto FS interneurons, thereby disinhibiting L4
excitatory neurons (Gibson et al., 2008; Patel et al., 2013). The
change in excitatory input to FS neurons is dependent on pre-
synaptic FMRP expression aswas also found in a separate study
of the reduction in excitatory connectivity between CA3 neurons
in slice culture (Hanson and Madison, 2007). Although similar in
their reliance on presynaptic Fmr1, the two forms of excitatory
synaptic weakening differ in that the former is due primarily to
a reduction in the probability of release, while the latter is due
to a reduced probability of connectivity. The two also differ in
their presumed functional consequences as one will lead to
disinhibition and circuit hyperexcitability, while the other will
lead to reduced circuit excitability. Both are also likely distinct
from the postsynaptic effects of Fmr1 on mGluR-dependent
LTD. These studies highlight the circuit level complexities that
arise when a single gene product can produce multiple distinct
cellular and synaptic phenotypes when acting in different cell
types or even in different compartments within the same cell.
Reduced excitation has also been posited as a key patho-
physiological mechanism in the autistic syndromes associated
with Shank3, PSD95, and a variety of associated PSD proteins.
(For reviews of the PSD and synaptic protein involved in develop-
mental disorders, see [Ebert and Greenberg, 2013; Ting et al.,
2012].) Specifically, deletion of neurexin-1b in adult mice results
in impaired glutamatergic transmission onto cortical pyramidal
neurons (Rabaneda et al., 2014) and neurexin-1a-deficient
mice also have a decrease in excitatory synapse function (Ether-
ton et al., 2009). Knockin of a Neuroligin 3 mutation associated
with autism, R704C, leads to a decrease in AMPA-mediated
transmission with no effect on NMNDA or GABAergic neuro-
transmission in the hippocampus (Etherton et al., 2011).
The Neuroligin-Neurexin complex binds to the synaptic scaf-
folding proteins SHANK1–3 at the postsynaptic densities of
excitatory synapses (Jiang and Ehlers, 2013). Deletions that
encompass SHANK3 and other genes produce Phelan-McDer-
mid syndrome associated with Autism, intellectual disability,
hypotonia, and seizures. These features are also present in dele-
tions and other mutations restricted to Shank3. Autism-associ-
ated Shank3 mutant mice have normal basal synaptic transmis-
sion but have reduced post-tetanic potentiation and LTP in the
CA1 area of the hippocampus which correlates with reductions
in GluA1 subunits and other PSD proteins (Wang et al., 2011).
Two independent models of Shank3 insufficiency found a
decrease in excitatory synaptic transmission and plasticity in
the hippocampus (Bozdagi et al., 2010) and the striatum (Pec¸a
et al., 2011). Intriguingly, duplications of Shank3 produce hyper-
activity, mania, and seizures in human patients and mice engi-neered with duplications display similar symptoms associated
with enhanced excitatory and reduced inhibitory synaptic trans-
mission (Han et al., 2013).
A Homeostatic Resolution
A common theme in the physiological studies of developmental
disorders reviewed above is that both excitatory and inhibitory
synapses are functionally altered. One difficulty in resolving
this issue arises in part because single genes that play major
roles in fundamental cellular processes like translation, RNA traf-
ficking, protein degradation, and the epigenetic regulation of
transcription are likely to have complex effects in multiple cell
types that together contribute to the network phenotype (Ra-
mocki and Zoghbi, 2008), but this pleiotropy is only part of the
problem. Another explanation for these disparities is that primary
changes in excitation or inhibition alter network activity, and this
change in activity can itself induce secondary changes. One
particularly powerful set of secondary changes is that engaged
by homeostatic plasticity mechanisms (Figure 2). Studies in a va-
riety of invertebrate (Davis, 2006; Marder and Goaillard, 2006)
and vertebrate (Pozo and Goda, 2010; Turrigiano, 2011; Turri-
giano and Nelson, 2004) model systems have identified a family
of mechanisms that adjust neuronal and synaptic function in or-
der to homeostatically regulate circuit activity. These act to
attempt to return network activity to a predetermined set point
following perturbations of activity. They occur via changes in
intrinsic neuronal excitability and in the strength and number of
excitatory and inhibitory synapses. Given the existence of
powerful homeostatic plasticity mechanisms, it can be difficult
to separate primary effects of disease-causing mutations from
compensatory changes in circuit function. In some cases, like
mutations of ARX, or Dravet’s Syndrome, it is fairly clear that
there are primary disruptions of critical functions of specific sub-
types of GABAergic interneurons. In other cases, like those mu-
tations in the SHANK proteins, or some of their PSD binding
partners, the primary deficit is fairly clearly at excitatory synap-
ses on glutamatergic neurons. In many other cases, however,
it is still hard to discern which changes are the ‘‘chicken’’ and
which are the ‘‘egg.’’
Initial deficits and homeostatic responses could be hard to
separate from the network and cellular homeostatic mecha-
nisms. Sparse, cell-type-specific knockout strategies can be
helpful for distinguishing cell-autonomous from network effects
(Bateup et al., 2013; Blackman et al., 2012; Chao et al., 2007;
Zhang et al., 2014), while temporal control of deletion (Cheval
et al., 2012) or rescue experiments (Garg et al., 2013; Giacometti
et al., 2007; Guy et al., 2007) can overcome developmental
compensation and uncover cell-autonomous homeostatic ef-
fects. However, even these refined genetic strategies must be
bolstered by careful functional analysis to distinguish, for
example, effects on output versus input synapses, or even post-
synaptic versus retrograde presynaptic effects. A part of the
issue is that the sparse cell-type-specific studies are necessary
to understand the primary deficit, but they will not recapitulate
the behavioral phenotype. On the other hand, full knockout ap-
proaches that do capture the behavioral aspects of a disorder
lack the brain region selectivity and are confounded by network
and homeostatic effects.Neuron 87, August 19, 2015 ª2015 Elsevier Inc. 689
Figure 2. Homeostatic Compensation
Regulates Excitation/Inhibition Ratio in
Cortical Networks
Proper neural network function relies on the bal-
ance between excitatory (green) and inhibitory
(red) input. Primary defects in excitation or inhibi-
tion can be corrected via secondary compensa-
tory mechanisms to restore balance and maintain
network function. When a cell receives reduced
excitation, secondary mechanisms downregulate
the amount of inhibitory input onto this cell. Simi-
larly, the excitatory input is decreased in response
to a deficit in inhibition. Hence changes in both
classes of synapses can appear similar following
diseasemechanisms that initially affect only one or
the other.
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models is challenging even if the initial insult is known. Although
there is an enormous diversity of synaptic connections, they may
be broadly categorized inmost brain areas into fivemain types of
connections: glutamatergic synapses that excite other glutama-
tergic neurons (recurrent excitatory synapses) or that excite
inhibitory neurons, GABAergic synapses that inhibit excitatory
neurons or that inhibit other GABAergic neurons (disinhibitory
synapses), and finally modulatory synapses (such asmonoamin-
ergic synapses). Each major connection type is likely to have a
separate set of homeostatic mechanisms that can be altered
or spared by a single mutation in ASD. Molecular mechanisms
specifying each connection type are likely to be modified inde-
pendently of the other types. Below, we review examples of
the molecular mechanisms underlying these processes for
each of the glutamatergic and GABAergic connection types. Ho-690 Neuron 87, August 19, 2015 ª2015 Elsevier Inc.meostatic plasticity of modulatory neu-
rons and synapses has been well studied
in invertebrate model systems (see
Marder and Goaillard 2006) but has
been much less studied in mammals.
Recurrent Excitation
Homeostatic mechanisms regulating
recurrent excitatory connections were
first studied in the neocortex, spinal
cord, hippocampus, and other structures
(see Turrigiano and Nelson, 2004 for re-
view). Molecular mechanisms that regu-
late the formation, function, andmodifica-
tion of the excitatory synapses onto other
excitatory cells have been extensively
described. For example, cell adhesion
proteins not only regulate the formation
of excitatory synapses but also contribute
to homeostatic changes that these syn-
apses undergo (Thalhammer and Cingo-
lani, 2014). Other studies have identified
the kinases and phosphatases involved
in homeostatic plasticity and have identi-
fied many of the core signaling pathways
involved in multiple forms of plasticity.
These include calcium signaling path-ways such as calcineurin, which has been shown to regulate
synaptic scaling (Kim and Ziff, 2014) and network adaptation to
activity changes (Casanova et al., 2013), and Ca(2+)/calmod-
ulin-dependent protein kinase II and IV (Hell, 2014), which can
target Ubiquitin-proteasome system to regulate synaptic
strength (Djakovic et al., 2012). There are numerous other path-
ways and molecules that are important homeostatic regulators
of the recurrent excitatory connections and are a subject of
many good reviews. What is clear, however, is that many of
these, like cell adhesion molecules, the ubiquitin-proteasome
system, and calcium, have been also implicated in ASD (Krey
and Dolmetsch, 2007; Mabb et al., 2011; Yang et al., 2014).
Inhibition
Early studies revealed that inhibitory synapses also undergo ho-
meostatic changes, although these in general occur in the oppo-
site direction from changes at excitatory synapses (Kilman et al.,
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leagues (Jones, 1993) has established that ongoing cortical ac-
tivity is required for the normal development and maintenance
of interneuron input and output synapses, intrinsic firing proper-
ties, morphology and expression of markers including GAD, par-
valbumin, and others. In a number of cases, these activity-
dependent effects have been traced to release of BDNF from
excitatory neurons (Hong et al., 2008; Peng et al., 2010; Woo
and Lu, 2006), and deletion of TrkB, the high-affinity receptor
for BDNF, selectively in forebrain interneurons reduces their
expression of key components of GABA synthesis and release
such as GAD65. However, the signaling mechanisms by which
activity in pyramidal neurons drives homeostatic changes in inhi-
bition are more complex. First, BDNF itself has a plurality of ac-
tions including apparently cell-autonomous effects on spine
density in excitatory neurons (English et al., 2012) as well as
acute suppressive effects on inhibitory transmission (Frerking
et al., 1998), both of which may contribute to its net effects in
some preparations being pro-epileptic, rather than homeostatic
(McNamara and Scharfman, 2012). Second, BDNF is not the only
activity-dependent signalingmolecule regulating forebrain inhib-
itory circuits (see below). Some of the complexity of BDNF
signaling reflects the complexity of its transcriptional regulation.
BDNF is transcribed from eight different promoters. One of
these, promoter IV, is the major activity-dependent promoter
active in the neocortex. Selective disruption of promoter IV
(Jiao et al., 2011; Sakata et al., 2009) or of the ability of the activ-
ity-dependent transcription factor CREB to bind to promoter IV
(Hong et al., 2008) selectively reduces inhibitory, but not excit-
atory, synaptic transmission. Synapses from parvalbumin-posi-
tive interneurons are selectively disrupted (Jiao et al., 2011).
Presumably, it is this signaling pathway that permits the precise
matching of PV+ inhibitory to excitatory synaptic strength onto
pyramidal cells and that permits this balance to be adjusted
following perturbations that alter sensory drive or pyramidal
neuron activity (House et al., 2011; Xue et al., 2014).
Altered BDNF signaling has been implicated in mouse models
of Fragile X, Rett, and Angelman Syndrome (Cao et al., 2013;
Chang et al., 2006; Lauterborn et al., 2007). These are among
the disorders that are characterized by a period of normal devel-
opment followed by regression and later seizure onset (Table 1).
The case of Rett Syndrome illustrates the complexity of under-
standing how disease causing mutations interact with activity-
dependent signaling pathways. BDNF was first identified as a
direct target of repression by the DNA-binding protein MeCP2,
the genemutated in the overwhelmingmajority of Rett Syndrome
cases. Studies in cultured neurons confirmed that activity (depo-
larization) caused phosphorylation of MeCP2, which, in turn,
derepressed BDNF expression (Zhou et al., 2006). Subsequent
in vivo studies found, however, that rather than contributing to
the symptoms of Mecp2 KO mice, BDNF overexpression allevi-
ated them, while reduced BDNF signaling exacerbated them
(Chang et al., 2006). Presumably, in vivo, diminished activity-
dependent release of BDNF (due to reduced activity) outweighs
the direct derepression mediated by loss of MeCP2. This
pathway could account for the cell autonomous ability of delet-
ing Mecp2 (Zhang et al., 2014) or possibly TSC1 (Bateup et al.,
2013) to reduce inhibitory input to pyramidal neurons.Another molecule that links excitatory network activity with
structural and functional changes in inhibitory function is the
transcription factor NPAS4 (Lin et al., 2008; Ramamoorthi
et al., 2011). Upregulation of NPAS4 following activity in CA1 py-
ramidal neurons results in enhancement of inhibitory connec-
tions onto these excitatory neurons through transcription of
late-response genes, including Bdnf (Lin et al., 2008). Thus, ac-
tivity in the excitatory cells is essential for proper inhibitory syn-
apse formation onto these cells. Consistent with this, NPAS4
knockout mice appear to be hyperactive, are prone to seizures,
and have deficits in social behaviors and cognitive functions
(Coutellier et al., 2012; Lin et al., 2008). On the other hand,
NPAS4 is also upregulated and induces a distinct transcriptional
program following activity in inhibitory neurons, which then in-
creases excitatory input onto these inhibitory cells (Spiegel
et al., 2014). Thus, the same transcription factor regulates synap-
tic function in excitatory and inhibitory cells to achieve a homeo-
static resolution in response to increased activity. Presumably,
there are additional factors yet to be identified, contributing to
activity-dependent regulation of cortical inhibition, particularly
with respect to other subtypes of interneurons besides FS cells.
Excitatory Synapses onto Inhibitory Cells
The strength of inhibition depends not only on regulation of pre-
and postsynaptic properties of inhibitory synapses, but also on
the excitatory synapses driving the firing of inhibitory neurons.
The best characterized inter-cellular signaling mechanism regu-
lating these synapses is that initiated by binding of the ligand
neuregulin 1 (Nrg1) to its receptor ErbB4 on parvalbumin-posi-
tive, fast-spiking (FS) interneurons. During early cortical develop-
ment, ErbB4 is critical for the proper migration of FS interneu-
rons. Subsequently ErbB4 regulates both the inhibitory outputs
and excitatory inputs of FS neurons (for reviews, see Buonanno,
2010; Rico and Marı´n, 2011). Specifically, loss of ErbB4 in inter-
neurons decreases the number of axo-axonic synapsesmade by
chandelier cells and decreases the number of excitatory synap-
ses made onto FS neurons. Conversely, overexpression of Nrg1
by pyramidal neurons or treatment with exogenous Nrg1 can in-
crease axo-axonic inhibitory synapses and increase excitatory
synapses onto FS neurons. A subsequent study in prefrontal cor-
tex confirmed a critical role for ErbB4 in regulating excitatory
synapses onto FS interneurons but failed to find an effect of em-
bryonic interneuron-specific deletion of the receptor on inter-
neuron migration or on interneuron output synapses (Yang
et al., 2013). Nrg1-ErB4 signaling may also acutely regulate
GABA release (Woo et al., 2007) and interneuron excitability (Li
et al., 2012; Tan et al., 2012).
Mutations in Nrg1 and ErbB4 are associated with schizo-
phrenia and deletion of ErbB4 has also recently been identified
in a case of profound developmental delay in speech and cogni-
tive abilities (Kasnauskiene et al., 2013). Studies of mutant mice
have also implicated enhanced Nrg1/ErbB4 signaling in AS
(Kaphzan et al., 2012). The recent history of attempts to unravel
how this pathway contributes to schizophrenia and cognitive
function is illustrative of the difficulty of disentangling direct
and secondary effects of disruptions in one leg of the excit-
atory-inhibitory circuit in cortex. Initial studies focused on the
role played by ErbBr and Nrg1 on excitatory synaptic transmis-
sion between pyramidal neurons. ErbB4 is present atNeuron 87, August 19, 2015 ª2015 Elsevier Inc. 691
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chemically with PSD-95. Loss-of-function studies suggested
loss of ErbB4 caused reduction in the number of dendritic spines
(Barros et al., 2009) and alterations of excitatory synapse func-
tion (Li et al., 2007). Application of Nrg1 could block the induction
or expression of hippocampal LTP and could depotentiate LTP
after induction (Kwon et al., 2005). Careful studies excluding
expression of ErbB4 in pyramidal neurons of neocortex and hip-
pocampus led several groups to conclude that perhaps the ef-
fects of Nrg1 and ErbB4 on excitatory synapses were not cell
autonomous. Recently, two groups directly tested for the depot-
entiation phenotype. Both found that conditional KO of ErbB4
restricted to interneurons blocked the ability of Nrg1 to produce
depotentiation of excitatory synapses. Although the same ge-
netic tests have not been carried out for changes in spines, it
has been suggested that these effects are also not cell autono-
mous (Rico and Marı´n, 2011).
Disinhibition
Although numerous studies have highlighted the importance of
GABAergic interneurons for regulating network activity in the
forebrain, very few of these have focused on inhibitory connec-
tions between interneurons. Early paired recording studies
demonstrated that within major interneuron classes, cells are
linked both by electrical (gap junction) and chemical (inhibitory)
synapses (Galarreta and Hestrin, 1999; Gibson et al., 1999). Dis-
inhibitory synapses between interneurons of distinct classes
have also recently been studied. Somatostatin-expressing inter-
neurons disinhibit cortical pyramidal neurons by directly inhibit-
ing fast-spiking parvalbumin-positive interneurons in layer 4 (Xu
et al., 2013). In auditory and medial prefrontal cortices, vasoac-
tive intestinal peptide-expressing interneurons provide inhibition
to somatostatin and parvalbumin-positive interneurons (Pi et al.,
2013). In the visual cortex, parvalbumin-expressing interneurons
inhibit each other, while somatostatin-expressing interneurons
strongly inhibit other types of inhibitory neurons (Pfeffer et al.,
2013). The behavioral and network effects of deficits in disinhibi-
tion are not well studied, although there is evidence that disinhi-
bition is important for network synchrony (Hu et al., 2011) and
associative fear learning (Letzkus et al., 2011). Unfortunately,
there is very little known about homeostatic regulation of these
various types of disinhibitory connections.
Circuit Homeostasis in ASD: Inadequate, Maladaptive,
and Targeted
The mechanisms mediating homeostatic plasticity are diverse
and include at a minimum changes in intrinsic excitability result-
ing from changing numbers, properties, or localization of
voltage-gated ion channels; pre- and postsynaptic changes in
the strength of excitatory and inhibitory synapses; and changes
in the numbers of these synapses. Given this large number of
homeostatic mechanisms, one might wonder why they fail to
regularize activity during developmental disorders. Why aren’t
primary changes in inhibitory or excitatory circuits fully compen-
sated by changes in other parts of the network? Here we
consider three possible explanations.
First, compensation may be initially adequate but may fail as
developmental abnormalities accumulate. This could occur if
the magnitude of the relevant homeostatic mechanisms are692 Neuron 87, August 19, 2015 ª2015 Elsevier Inc.insufficient relative to the magnitude of the initial pathological
change (e.g., scaling up of excitatory synapses in response to
global reductions in activity is typically 25%–50% over the
course of a 1–2 day activity manipulation). The inability of
compensation to keep up may explain, for example, why symp-
toms in some ASDs are relatively mild in early development and
only become pronounced later (Table 1). In addition, changes in
activity may engage Hebbian synaptic plasticity, which acts to
enhance or decrease synaptic transmission in the same direction
as the change in the input (i.e., strengthening synapses between
highly active neurons and weakening those between inactive or
less active neurons). Thus, Hebbian plasticity mechanisms will
act in the opposite direction of homeostatic compensation and
exacerbate the defect. For example, if inhibitory transmission
is reduced, this is likely to enhance the ability of excitatory syn-
apses to undergo Hebbian LTP, which will in turn create a further
imbalance in activity making compensation all the more difficult.
This nonlinear interaction could contribute to the frequent
switch-like onset and subsequent persistence of seizures,
although the question of how or even whether ‘‘seizures beget
seizures’’ is controversial (Ben-Ari, 2008; Blume, 2006; Hauser
and Lee, 2002). Perhapsmore importantly, compensationmech-
anisms may themselves be targets of the underlying pathology.
For example, at least some of the complex single gene disorders
(Rett, FRX, TS, and ARX) result in blockade of synaptic scaling.
As noted above, this has been demonstrated for Rett. For FRX,
blockade of scaling up has also been described (Soden and
Chen, 2010). Other studies have shown that both pre-(Doyle
et al., 2010) and postsynaptic (Goold and Nicoll, 2010) forms of
scaling down depend on transcription and/or protein synthesis
and so might be expected to be altered by disorders that affect
translation and RNA and protein stability.
A second reason that homeostatic mechanisms may not alle-
viate developmental disorders is that they can becomemaladap-
tive. For example, since inhibitory neurons receive input from
excitatory neurons, in response to a decrease in excitatory activ-
ity, the output of the inhibitory neurons is also decreased via
direct loss of input or through secondary homeostatic changes
to maintain the balance of inhibition and excitation (Hartman
et al., 2006; Xue et al., 2014). This response, initially helpful,
can potentially move the excitation/inhibition ratio past the bal-
ance point and result in the opposite problem: too little inhibition
to prevent runaway synchronous activity (Figure 3). Theoretical
studies have shown that epilepsy-like bursting activity in isolated
neocortex following loss of afferent signals can be accounted for
by homeostatic plasticity (Houweling et al., 2005). In addition, a
similar phenomenon has been demonstrated in a central pain
syndrome model in which a spinothalamic tract lesion results
in hyperexcitation in the thalamus (Wang and Thompson,
2008). We hypothesize that late seizures occurring in develop-
mental disorders like Rett Syndrome that are characterized by
overall decreases in forebrain activity may reflect this kind of
maladaptive compensation.
Lastly, in a multilayered network, like that linking peripheral
sensory structures to the thalamus to primary sensory cortices
and then to multiple levels of higher-order cortices, the faithful
propagation of signals from one layer to the next requires that
excitation, inhibition, and intrinsic excitability in each layer be
Figure 3. Faithful Signal Propagation in
Multilayered Cortical Networks May
Require Higher-Order Layers to
Compensate for Altered Activity in Lower
Layers
Cortical networks can be schematized as inter-
connected layers of neurons. Activity in the ‘‘input
layer’’ of primary sensory cortices is driven by
sensory inputs, while activity in higher-order as-
sociation and limbic regions depends to a greater
degree on activity in preceding layers.
(A) During normal development, excitation and
inhibition are balanced to preserve appropriate
activity levels across synaptically connected brain
regions with the activity of the cells in each layer
adjusted to the amount of input this layer receives.
(B) If the balance is perturbed so that, for example,
input layers have reduced activity (indicated by
normal red inhibitory but reduced green excitatory
activity), homeostatic mechanisms compensate
for the defect and upregulate the excitability of circuits in higher-order Association and Limbic regions (indicated by a darker shade of green and lighter shade of
red in some neurons) in an attempt to maintain normal levels of propagating activity. However, if not perfectly balanced, this can lead to overactivity in higher-
order regions coexisting with reduced activity in lower-order regions. Networks in higher-order regions with enhanced excitation and reduced inhibition may be
brittle and prone to develop epileptiform activity.
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agation is close to one. If this ‘‘gain’’ is significantly below one,
propagation is likely to fail prior to reaching the higher-order re-
gions; if the gain is significantly above one, the signal is likely to
saturate and may lead to hyper-synchrony and epilepsy
(Figure 3; see also Turrigiano and Nelson, 2004). This scenario
becomes even more likely when the homeostatic machinery is
compromised by the mutation that caused the imbalance in
the first place (Toro et al., 2010; Wondolowski and Dickman,
2013). It has long been known that different forebrain regions
have differing propensities to generate seizures, with the highest
propensity occurring in the hippocampus and other limbic struc-
tures (McCormick and Contreras, 2001). This may reflect differ-
ences in circuitry but may also reflect the relative balance be-
tween Hebbian plasticity mechanisms that enhance circuit
excitability and homeostatic plasticity mechanisms that dampen
circuit excitability. We hypothesize that as developmental disor-
ders progress, homeostatic mechanisms are insufficient to
restore normal activity in early cortical areas and are actually
maladaptive in higher-order limbic regions like the hippocam-
pus, where reduced excitatory drive leads to trophic downregu-
lation of inhibitory circuits that normally prevent epileptic activity
from developing (Figure 3). Developing a more complete under-
standing of the signaling pathways and effector molecules
important for various forms of homeostatic plasticity may allow
this hypothesis to be tested. In addition, such an understanding
may provide strategies for selectively enhancing or restoring ho-
meostatic plasticity where it is beneficial and/or inhibiting mal-
adaptive forms of plasticity.
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